Houston, Texas — According to state and local development sources, Marker Therapeutics plans to invest $12,000,000.00 to build out 57,310 square feet of new space in Houston. The company plans to occupy the new space at 4551 Kennedy Commerce Drive in Houston, on or about 7/1/2024. According to the company website We are a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Markers unique cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize multiple tumor associated antigens (multiTAA) and kill tumor cells expressing those targets. Once infused into patients, this population of multiTAA-specific T cells attacks multiple tumor targets and acts to activate the patients immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies.

To learn more about Marker Therapeutics, visit http://markertherapeutics.com/

Company Contact:
Juan Vera, Chief Executive Officer
713-400-6400

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.